MASLD is the hepatic manifestation of metabolic syndrome (metS), driven by genetic variants like PNPLA3 rs738409 G and strongly associated with metabolic comorbidities, including obesity, T2DM, hyperlipidaemia and hypertension (8–10). This evidence concerns the gene PNPLA3 and metabolic syndrome.